Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.

Asian Pac J Allergy Immunol 2019 Jan 13. Epub 2019 Jan 13.

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Urticarial vasculitis (UV) is a rare form of cutaneous leukocytoclastic vasculitis with persistent urticarial lesions. UV may be severe and refractory to standard treatment including antihistamines, anti-inflammatories, antimalarials, corticosteroids and immunosuppressants. Omalizumab, an anti-IgE antibody, is approved for chronic spontaneous urticaria. However, its benefit for UV remains controversial. We report, herein, three patients with normocomplementemic UV and angioedema. All patients were diagnosed with chronic urticaria preceding the presentation of painful urticarial plaques. The diagnosis of UV was confirmed by skin biopsy and/or direct immunofluorescence. All patients had none or minimal response to standard treatments. Initial omalizumab dosing of 150 mg was administered subcutaneously (SC), however, increment to 300 mg monthly was necessary in 2 patients to control the disease. All 3 patients remained in complete remission after minimum follow up period of 9 months. To conclude, omalizumab has shown to be beneficial for severe normocomplementemic UV in our series.

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-050918-0402DOI Listing
January 2019
14 Reads

Publication Analysis

Top Keywords

urticarial vasculitis
8
report three
8
patients
5
preceding presentation
4
diagnosis confirmed
4
plaques diagnosis
4
urticarial plaques
4
painful urticarial
4
presentation painful
4
confirmed skin
4
immunofluorescence patients
4
patients minimal
4
direct immunofluorescence
4
and/or direct
4
skin biopsy
4
biopsy and/or
4
urticaria preceding
4
diagnosed chronic
4
urticaria benefit
4
benefit remains
4

Similar Publications